NeoStem
420 Lexington Avenue
Suite 350
New York, New York 10170
Telephone: 1.212.584.4180

TransformingMedicine

Image for About NeoStem

About NeoStem

NeoStem develops and manufactures cell therapies for its proprietary technology platforms and for the cell therapy industry.

Learn More

 

TargetingCancer

Image for Cancer Immunotherapy

Cancer Immunotherapy

NeoStem is developing therapeutics that target cancer initiating cells, starting with a Phase 3 trial for melanoma.

Learn More 

Enhancingthe body’s healing response

Image for Ischemic Repair

Ischemic Repair

NeoStem is developing therapies to repair ischemia through the development and formation of new blood vessels.

Learn More

Rebalancingthe immune system

Image for Immune Modulation

Immune Modulation

NeoStem seeks to develop cell therapies using a person’s own immune cells as a therapeutic product to treat disorders of the immune system.

Learn More

Unlockingthe power of VSELs

Image for Tissue Regeneration

Tissue Regeneration

NeoStem is exploring the therapeutic potential of very small embryonic-like stem cells (VSELsTM) to regenerate or repair damaged or diseased tissues.

Learn More

Leveragingexperience in cell therapy

Image for Contract Manufacturing

Contract Manufacturing

NeoStem’s subsidiary, PCT, provides outsourced manufacturing capabilities to the cell therapy industry while supporting the development of NeoStem’s proprietary cell therapy products.

Learn More

News + Events

News + Events

NeoStem Secures Debt Facility: Strengthens Balance Sheet with Non-Dilutive Financing, Company Provides Update on Remaining Milestones for 2014 September 29, 2014 - Learn More
NeoStem Announces Licensing of Patent Portfolio from the Rockefeller University Expanding its Cancer Immunotherapy Intellectual Property Portfolio September 11, 2014 - Learn More
NeoStem Letter to Shareholders September 8, 2014 - Learn More

NeoStem Blog

Seizing an Opportunity to Fight Cancer

Strategic acquisitions have been the cornerstone of NeoStem’s growth and have been selected in order to p.... Read More

Insider Buying

On July 1st, approximately 14,456 shares of the Company’s common stock were purchased by employees of th.... Read More